• 1
    Cafardi J, Rakatansky H, Alarcon G. Gastrointestinal manifestations of rheumatoid arthritis. In: Asherson R, Font J, Ramos-Casals M, Rodes J, editors. Handbook of systemic autoimmune diseases. Vol. 8. Amsterdam: Elsevier; 2008. p. 10917.
  • 2
    Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62: 1592601.
  • 3
    Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 11523.
  • 4
    Straube S, Tramer MR, Moore RA, Derry S, McQuay HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009; 9: 41.
  • 5
    Humes DJ, Fleming KM, Spiller RC, West J. Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study. Gut 2011; 60: 21924.
  • 6
    Goh H, Bourne R. Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case-control study. Ann R Coll Surg Engl 2002; 84: 936.
  • 7
    Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology 2011; 140: 142733.
  • 8
    Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 1739.
  • 9
    Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective—1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51: 816.
  • 10
    Chan FK, Cryer B, Goldstein JL, Lanas A, Peura DA, Scheiman JM, et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 2010; 37: 16774.
  • 11
    Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104: 163341.
  • 12
    Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, Ponce M, Quintero E, Perez-Aisa MA, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 2011; 33: 58591.
  • 13
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 124755.
  • 14
    Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 2419.
  • 15
    Gu NY, Huang XY, Fox KM, Patel VD, Baumgartner SW, Chiou CF. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits 2010; 2: 3519.
  • 16
    Briesacher B, Kamal-Bahl S, Hochberg M, Orwig D, Kahler KH. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Arch Intern Med 2004; 164: 167984.
  • 17
    Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum 2009; 61: 75563.
  • 18
    Nair KV, Tang B, Van Den Bos J, Zhang V, Saseen JJ, Naim A, et al. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. Curr Med Res Opin 2009; 25: 30314.
  • 19
    Petri H, Maldonato D, Robinson NJ. Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database. BMC Musculoskelet Disord 2010; 11: 247.
  • 20
    Curtis JR, Chen S, Werther W, John A, Johnson D. Validation of ICD-9-CM codes to identify GI perforation events in administrative claims data among hospitalized rheumatoid arthritis patients. Pharmacoepidemiol Drug Saf 2011; 20: 11508.
  • 21
    Curtis JR, Xie F, Chen L, Spettell C, McMahan RM, Fernandes J, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 2011; 63: 34651.
  • 22
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 46573.